| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121, 2018 | 4161 | 2018 |
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 2986 | 2015 |
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ... Journal of the National Cancer Institute 98 (4), 262-272, 2006 | 2375 | 2006 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous … M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ... The Lancet Oncology 17 (4), 425-439, 2016 | 1923 | 2016 |
| Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition … S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ... Journal of clinical oncology 31 (7), 860-867, 2013 | 1854 | 2013 |
| Palbociclib in hormone-receptor–positive advanced breast cancer NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ... New England Journal of Medicine 373 (3), 209-219, 2015 | 1801 | 2015 |
| Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ... Journal of the National Cancer Institute 98 (17), 1183-1192, 2006 | 1544 | 2006 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1471 | 2020 |
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ... Annals of oncology 25 (8), 1544-1550, 2014 | 1407 | 2014 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1228 | 2020 |
| Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The lancet oncology 21 (1), 44-59, 2020 | 1206 | 2020 |
| Overall survival with palbociclib and fulvestrant in advanced breast cancer NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ... New England journal of medicine 379 (20), 1926-1936, 2018 | 1181 | 2018 |
| Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative … C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ... Journal of clinical oncology 33 (9), 983-991, 2015 | 1155 | 2015 |
| CD4+ follicular helper T cell infiltration predicts breast cancer survival C Gu-Trantien, S Loi, S Garaud, C Equeter, M Libin, A De Wind, M Ravoet, ... The Journal of clinical investigation 123 (7), 2873-2892, 2013 | 1121 | 2013 |
| Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ... Clinical cancer research 13 (11), 3207-3214, 2007 | 1102 | 2007 |
| Definition of clinically distinct molecular subtypes in estrogen receptor–positive breast carcinomas through genomic grade S Loi, B Haibe-Kains, C Desmedt, F Lallemand, AM Tutt, C Gillet, P Ellis, ... Journal of clinical oncology 25 (10), 1239-1246, 2007 | 953 | 2007 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 945 | 2020 |
| Clinical relevance of host immunity in breast cancer: from TILs to the clinic P Savas, R Salgado, C Denkert, C Sotiriou, PK Darcy, MJ Smyth, S Loi Nature reviews Clinical oncology 13 (4), 228-241, 2016 | 943 | 2016 |
| ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ... Annals of oncology 32 (12), 1475-1495, 2021 | 942 | 2021 |
| Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ... The lancet oncology 18 (8), 1009-1021, 2017 | 935 | 2017 |